Program
Ibuprofen
Also written as “ibuprofen”, “Intravenous ibuprofen” and “Ibuprofen/acetaminophen”.
Its studies are mostly in Pain · Pain, Postoperative · Osteoarthritis · Fever · Osteoarthritis, Knee, led by 36 companies.
Drug pageIbuprofen: every studyMany companies study it; this page follows only the 101 they lead. All 433 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 150 open or running | phase 4since Aug 22, 2008 | Aug 22, 2008 | none ahead |
| Cumberland Pharmaceuticalsits history only | 90 open or running | phase 4since Apr 12, 2011 | Sep 22, 2005 | none ahead |
| Johnson & Johnsonits history only | 70 open or running | phase 4since Oct 14, 2005 | Oct 14, 2005 | none ahead |
| Boehringer Ingelheimits history only | 60 open or running | phase 3since Aug 22, 2013 | Jul 26, 2010 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 60 open or running | phase 1since Jan 20, 2010 | Jan 20, 2010 | none ahead |
| Reckittits history only | 60 open or running | phase 3since Oct 26, 2010 | Oct 26, 2010 | none ahead |
| AFT Pharmaceuticalsits history only | 51 open or running | phase 3since Aug 16, 2011 | Apr 14, 2010 | Mar 2027phase 3 · NCT07225634 |
| Strategic Science & Technologiesits history only | 40 open or running | phase 3since Oct 11, 2012 | Oct 11, 2012 | none ahead |
| Angelini Pharmaits history only | 30 open or running | phase 1since Jun 17, 2015 | Jun 17, 2015 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 4since Mar 28, 2013 | Sep 5, 2006 | none ahead |
| Hypera Pharmaits history only | 30 open or running | phase 4since May 20, 2011 | Jul 28, 2010 | none ahead |
| Pierre Fabreits history only | 30 open or running | phase 3since Feb 5, 2013 | Feb 10, 2012 | none ahead |
| Amgenits history only | 20 open or running | phase 4since Mar 20, 2012 | Mar 19, 2007 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 20 open or running | phase 3since Jul 18, 2024 | Jun 15, 2022 | none ahead |
| Medherantits history only | 20 open or running | phase 1since Aug 16, 2018 | Aug 16, 2018 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 20 open or running | phase 3since Mar 22, 2012 | Mar 22, 2012 | none ahead |
| Overseas Pharmaceuticalsits history only | 21 open or running | phase 3since Dec 20, 2021 | Feb 4, 2021 | none ahead |
| Oxford Pharmascienceits history only | 20 open or running | phase 1since Aug 5, 2015 | Aug 5, 2015 | none ahead |
| Perrigo | 20 open or running | phase 1since Dec 5, 2008 | Dec 5, 2008 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 10 open or running | phase 3since Mar 8, 2016 | Mar 8, 2016 | none ahead |
| BioChemicsits history only | 10 open or running | phase 2since Dec 15, 2011 | Dec 15, 2011 | none ahead |
| Biomendi S.A.U.its history only | 10 open or running | phase 3since Sep 25, 2014 | Sep 25, 2014 | none ahead |
| Futura Medical Developmentsits history only | 10 open or running | phase 1since Jan 20, 2016 | Jan 20, 2016 | none ahead |
| Future Sciene Technologyits history only | 10 open or running | phase 4since Dec 11, 2014 | Dec 11, 2014 | none ahead |
| HALEONits history only | 10 open or running | phase 1since Dec 12, 2025 | Dec 12, 2025 | none ahead |
| Hamad Medicalits history only | 10 open or running | early phase 1since Oct 7, 2019 | Oct 7, 2019 | none ahead |
| Laboratório Teuto Brasileiro S/Aits history only | 10 open or running | phase 3since Mar 22, 2011 | Mar 22, 2011 | none ahead |
| Lahore Medical Research Center, LLPits history only | 10 open or running | phase 3since Feb 23, 2024 | Feb 23, 2024 | none ahead |
| Menarini Groupits history only | 10 open or running | phase 1since Jun 17, 2025 | Jun 17, 2025 | none ahead |
| Merckits history only | 10 open or running | phase 1since Nov 28, 2007 | Nov 28, 2007 | none ahead |
| QC Kinetixits history only | 10 open or running | phase 2since Feb 6, 2023 | Feb 6, 2023 | none ahead |
| Sanofiits history only | 10 open or running | phase 3since Aug 31, 2011 | Aug 31, 2011 | none ahead |
| SCOLR Pharmaits history only | 10 open or running | phase 3since Jun 26, 2008 | Jun 26, 2008 | none ahead |
| Simbec Researchits history only | 10 open or running | phase 1since Sep 16, 2014 | Sep 16, 2014 | none ahead |
| Spherium Biomedits history only | 10 open or running | phase 2since Nov 10, 2015 | Nov 10, 2015 | none ahead |
| X-pert Medits history only | 10 open or running | phase 1since Jan 22, 2010 | Jan 22, 2010 | none ahead |
Also a collaborator on its studies: Premier Research Group, Parexel, Aptuit, Cross Research, Pharma Consulting Group AB, Pivotal S.L. and AAIPharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Perrigo only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 5, 2008First studies: 2 phase 1 studies in BioequivalencyFirst studyNCT00804440, NCT00803946
TargetBeta
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 2 Perrigo leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00804440Bioequivalency | 1 | Completed | Jan 2004 | 30 |
| NCT00803946Bioequivalency | 1 | Completed | Nov 2003 | 30 |
How it is read
Names in the registry
- “Ibuprofen”, 40 entries
- “ibuprofen”, 10 entries
- “Intravenous ibuprofen”, 5 entries
- “Ibuprofen/acetaminophen”, 4 entries
- “ibuprofen + caffeine”, 3 entries
Codes read as this program: SST0225.
Conditions, from the studies’ own filings
- Pain, 28 studies
- Pain, Postoperative, 6 studies
- Osteoarthritis, 5 studies
- Fever, 5 studies
- Osteoarthritis, Knee, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.